Celldex Therapeutics, Inc.
CLDX evidence brief
What we can confirm
- Market Cap:
- $3.07B
What it means
What to watch
Prepared research question
What matters most for CLDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLDX
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapies for inflammatory diseases, with its lead candidate barzolvolimab recently achieving positive Phase 3 results in chronic spontaneous urticaria.
Key risk: No approved products
Market Cap
$3.07B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapies for inflammatory diseases, with its lead candidate barzolvolimab recently achieving positive Phase 3 results in chronic spontaneous urticaria.
- Lead candidate barzolvolimab met primary and key secondary endpoints in two Phase 3 CSU trials (EMBARQ-CSU1 and EMBARQ-CSU2) [news · 2026-09-22].
- Cash, cash equivalents and marketable securities totaled $717.6 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Latest reported financials (as of 2026-06-30): cash & equivalents $47.5M; total revenue $0.0M; net income -$73.5M; shareholders' equity $714.6M [sec].
- Phase 2 study of barzolvolimab in Prurigo Nodularis did not meet primary or key secondary endpoints at Week 12 [sec_mda · as of 2026-08-06].
- Phase 1 proof-of-mechanism study of a next-generation bispecific antibody in mild to moderate asthma was initiated in January 2026 [sec_mda · as of 2026-05-07].
What works
- Barzolvolimab has demonstrated a well-tolerated safety profile across all studies reported to date [sec · filed 2026-04-29].
- The company has a substantial cash position of $717.6 million as of June 30, 2026, providing runway for ongoing development [sec_mda · as of 2026-08-06].
- Positive Phase 3 data in CSU supports potential registration and commercial opportunity [news · 2026-09-22].
- The bispecific antibody platform is being expanded to target additional inflammatory disease pathways [sec · filed 2026-04-29].
What to weigh
- The company has had recurring losses and incurred a net loss of $152 million (as of June 30, 2026) [sec_mda · as of 2026-08-06].
- Barzolvolimab failed to meet primary or key secondary endpoints in a Phase 2 Prurigo Nodularis study [sec_mda · as of 2026-08-06].
- Revenue is currently $0.0M (as of 2026-06-30), with no approved products generating sales [sec].
- Future funding depends on uncertain milestone payments and the company may need to raise additional capital [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Barzolvolimab met primary endpoints in two Phase 3 CSU trials
“Celldex Therapeutics (NASDAQ:CLDX) shares gained 8% on Tuesday after the company reported positive topline results from two Phase 3 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoints and all key secondary endpoints”
News · September 22, 2026
Cash position as of June 30, 2026
“At June 30, 2026, our principal sources of liquidity consisted of cash, cash equivalents and marketable securities of $717.6 million.”
SEC MD&A · August 6, 2026
Phase 2 PN study did not meet endpoints
“In July 2026, we shared topline results that showed the trial did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.”
SEC MD&A · August 6, 2026
Barzolvolimab safety profile
“Barzolvolimab has demonstrated a well-tolerated safety profile across all studies reported to date.”
SEC filings · April 29, 2026
Catalyst timeline
- 2023-06-01 · Phase 2 start for barzolvolimab in Eosinophilic Esophagitis (EvolvE study) — Initiation of a Phase 2 randomized, double-blind, placebo-controlled study in adults with active EoE.
- 2024-04-12 · Phase 2 start for barzolvolimab in Prurigo Nodularis — Initiation of a Phase 2 study in patients with Prurigo Nodularis.
- 2024-07-11 · Phase 3 start for barzolvolimab in CSU (EMBARQ-CSU1) — Initiation of a Phase 3 randomized, double-blind, placebo-controlled study in chronic spontaneous urticaria.
- 2024-07-19 · Phase 3 start for barzolvolimab in CSU (EMBARQ-CSU2) — Initiation of a second Phase 3 study in chronic spontaneous urticaria.
Risks & what to watch (4)›
Key risks
- No approved products — Company has $0.0M revenue as of 2026-06-30 and no marketed products [sec].
- Clinical trial failure risk — Barzolvolimab failed Phase 2 in Prurigo Nodularis, highlighting pipeline uncertainty [sec_mda · as of 2026-08-06].
- Recurring net losses — Net loss of $152 million as of June 30, 2026, with ongoing R&D spending [sec_mda · as of 2026-08-06].
- Dependence on milestone payments — Future liquidity depends on uncertain milestone from SRS Settlement Agreement [sec_mda · as of 2026-05-07].
What to watch
- Topline data from barzolvolimab Phase 2 in prurigo nodularis and Phase 2 in Alzheimer's disease expected summer 2026 and late 2026 [sec · filed 2026-04-29].
- Data from multiple ascending dose and subcutaneous administration portions of Phase 1 bispecific antibody study anticipated Q3 2026 [sec_mda · as of 2026-05-07].
- Potential regulatory filing for barzolvolimab in CSU following positive Phase 3 results [news · 2026-09-22].
- Cash runway and ability to fund operations without additional financing [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Celldex Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Celldex Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
229
Total value held
$2.23B
| Holder | Shares | Value |
|---|---|---|
| wellington management group llp | 8,560,476 | $271.5M |
| kynam capital management, lp | 5,840,567 | $185.3M |
| blackrock, inc. | 5,369,885 | $170.3M |
| fmr llc | 3,749,048 | $118.9M |
| point72 asset management, l.p. | 3,229,939 | $102.5M |
| vanguard capital management llc | 2,960,895 | $93.9M |
| state street corp | 2,804,168 | $88.9M |
| commodore capital lp | 2,696,616 | $85.5M |
| eversept partners, lp | 1,788,016 | $56.7M |
| geode capital management, llc | 1,688,074 | $53.6M |
Showing top 10 of 229 institutional holders of Celldex Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.5%
- Days to cover
- 6.7
- Shares short
- 7,599,353
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Celldex Therapeutics, Inc.?
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapies for inflammatory diseases, with its lead candidate barzolvolimab recently achieving positive Phase 3 results in chronic spontaneous urticaria.
Who is the CEO of Celldex Therapeutics, Inc.?
Mr. Anthony S. Marucci M.B.A. is the chief executive officer of Celldex Therapeutics, Inc. (CLDX).
Where is Celldex Therapeutics, Inc. headquartered?
Celldex Therapeutics, Inc. (CLDX) is headquartered in Hampton, NJ, United States.
What therapeutic areas does Celldex Therapeutics, Inc. focus on?
Celldex Therapeutics, Inc. develops therapies across Oncology, Immunology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.